Self Expanding TAVR (29mm) via Percutaneous Femoral Access in Patient with Metastatic Cancer

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Self Expanding TAVR (29mm) via Percutaneous Femoral Access in Patient with Metastatic Cancer

By Mount Sinai Structural Heart Live Cases FEATURING Samin Sharma, Annapoorna Kini

1,241 views

March 26, 2015

A 76 year-old female with H/O multiple PCI’s and metastatic breast cancer presented with progressive ...
read more ↘ symptomatic severe aortic stenosis, confirmed on cath with AVA 0.6 sq cm. TTE revealed severe AS, peak/mean aortic gradient = 64/48 mmHg, AVA = 0.6 sq cm, aortic peak velocity = 4.2 m/sec and LVEF 60%. CT angio showed minimum diameters of 0.8 x 0.8 cm for Right and 0.8 x 0.7 cm for the Left common femoral arteries and aortic annulus of 2.1 x 2.7 cm (average 2.4). The STS risk mortality is 4.2 and the Logistic Euroscore mortality is 11.7. Patient was determined to be extreme risk for surgical AVR due to metastatic cancer (responding to chemotherapy) with projected life expectancy of 2-3 years. Patient is now planned for CoreValve TAVR (29mm) via percutaneous femoral access under conscious sedation.

TAVR Live Case 1 October 14 2014
↖ read less

4 Comments